Atrial fibrillation ablation: A cost or an investment?

Europace

Volumn 13, Issue SUPPL. 2, 2011, Pages

  Kautzner, Josef ^a   Bulkova, Veronika ^a   Hindricks, Gerhard ^b   Maniadakis, Nikos ^c   Della Bella, Paolo ^d   Jaïs, Pierre ^e   Kuck, Karl Heinz ^f  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Ablation; Atrial fibrillation; Cost; Cost effectiveness; Quality of life

Indexed keywords

ARTICLE; CATHETER ABLATION; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE;

ARRHYTHMIAS, CARDIAC; CATHETER ABLATION; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; EUROPE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INVESTMENTS; PREVALENCE; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 79955611687     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur084     Document Type: Article

References (35)

1. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66. (Pubitemid 28402090)
2. Haissaguerre M, Shah DC, Jais P, Hocini M, Yamane T, Deisenhofer I et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000;102:2463-5.
3. Chen SA, Hsieh MH, Tai CT, Tsai CF, Prakash VS, Yu WC et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999;100:1879-86. (Pubitemid 29511141)
4. Pappone C, Oreto G, Lamberti F, Vicedomini G, Loricchio ML, Shpun S et al. Catheter ablation of paroxysmal atrial fibrillation using a 3D mapping system. Circulation 1999;100:1203-8. (Pubitemid 29426596)
5. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. Europace 2007;9:335-79.
6. Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, Sriratanasathavorn C, Pooranawattanakul S, Punlee K et al. A randomised clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai 2003;86(Suppl 1):S8-16.
7. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. J Am Coll Cardiol 2006;48:2340-7. (Pubitemid 44856763)
8. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomised, controlled study (Catheter Ablation for the Cure of Atrial Fibrillation Study). Eur Heart J 2006;27:216-21. (Pubitemid 43069040)
9. Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118:2498-505.
10. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634-40. (Pubitemid 40744248)
11. Cheema A, Vasamreddy CR, Dalal D, Marine JE, Dong J, Henrikson CA et al. Long-term single procedure efficacy of catheter ablation of atrial fibrillation. J Interv Card Electrophysiol 2006;15:145-55. (Pubitemid 44510957)
12. Shah AN, Mittal S, Sichrovsky TC, Cotiga D, Arshad A, Maleki K et al. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol 2008;19:661-7.
13. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003;42:185-97. (Pubitemid 36851403)
14. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006;354: 934-41.
15. Haissaguerre M, Sanders P, Hocini M, Takahashi Y, Rotter M, Sacher F et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. J Cardiovasc Electrophysiol 2005;16:1125-37.
16. Chen MS, Marrouche NF, Khaykin Y, Gillinov AM,Wazni O, Martin DO et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004;43:1004-9. (Pubitemid 38352980)
17. Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-83.
18. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5. (Pubitemid 32424106)
19. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the task force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12: 1360-420.
20. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90: 286-92. (Pubitemid 38250721)
21. Moeremans K, Aliot E, Chillou C, Annemans L, Le Pen C, de Jong P. Second line pharmacological management of paroxysmal and persistent atrial fibrillation in France: a cost analysis. Value Health 2000;6:407-16. (Pubitemid 32066648)
22. Le Heuzey JY, Paziaud O, Piot O, Said MA, Copie X, Lavergne T et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004;147: 121-6. (Pubitemid 38037407)
23. Ringborg A, Nieuwlaat R, Lindgren P, Jönsson B, Fidan D, Maggioni AP et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008;10:403-11. (Pubitemid 351767678)
24. Bulkova V, Fiala M, Chovancik J, Wichterle D, Cihák R, Branny M et al. Conventional treatment of atrial fibrillation in the Czech Republic managed by outpatient cardiologist. Overview of diagnostic and treatment procedures, pharmacological treatment and hospitalisation. Vnitr Lek 2008;54:36-44. (Pubitemid 351251902)
25. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007;18:628-33. (Pubitemid 46800517)
26. Natale A, Raviele A, Arentz T, Calkins H, Chen SA, Hafi "ssaguerre M et al. Venice chart international consensus document on atrial fibrillation ablation. J Cardiovasc Electrophysiol 2007;18:560-80. (Pubitemid 46650353)
27. Andrikopoulos G, Tzeis S, Maniadakis N, Mavrakis HE, Vardas PE. Cost effectiveness of atrial fibrillation catheter ablation. Europace 2009;11:147-51.
28. Weerasooriya R, Jais P, Le Heuzey JY, ScaveéCC, Choi KJ, Macle L et al. Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin electrophysiol 2003;26(1 Pt 2):292-4. (Pubitemid 36399158)
29. Khaykin Y, Morillo CA, Skanes AC, McCracken A, Humphries K, Kerr CR. Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:907-13. (Pubitemid 47342400)
30. Khaykin Y, Wang X, Natale A, Wazni OM, Skanes AC, Humphries KH et al. Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: an economic valuation of the RAAFT pilot study. J Cardiovasc Electrophysiol 2009;20:7-12.
31. Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol 2006;47:2513-20. (Pubitemid 43866357)
32. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 2009; 2:362-9.
33. Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S et al. Curative catheter ablation in atrial fibrillation and typical atrial fiutter: systematic review and economic evaluation. Health Technol Assess 2008;12:iii-iv, xi-xiii, 1-198.
34. Bertaglia E, Stabile G, Senatore G, Colella A, Del Greco M, Goessinger H et al. A clinical and health-economic evaluation of pulmonary vein encircling ablation compared with antiarrhythmic drug treatment in patients with persistent atrial fibrillation (Catheter Ablation for the Cure of Atrial Fibrillation-2 study). Europace 2007;9:182-5. (Pubitemid 46404165)
35. http://www.clinicaltrials.gov/ct2/show/NCT00911508fiterm=CABANA&rank= 1